THE CASE VARIANT TRANSLOCATION T(3;9;22)(P24;Q34;Q11) IN CHRONIC MYELOID LEUKEMIA
Vol. 64 No. 6 (2018), CLINICAL CASE
Vol. 64 No. 6 (2018)

THE CASE VARIANT TRANSLOCATION T(3;9;22)(P24;Q34;Q11) IN CHRONIC MYELOID LEUKEMIA

CLINICAL CASE
https://doi.org/10.37469/0507-3758-2018-64-6-810-814
Published 01.06.2018
Kodirzhon Boboev
Scientific research institute of hematology and blood transfusion of the Ministry of Health of the Republic of Uzbekistan
Yuliana Assesorova
Scientific research institute of hematology and blood transfusion of the Ministry of Health of the Republic of Uzbekistan
Kh. Karimov
Scientific research institute of hematology and blood transfusion of the Ministry of Health of the Republic of Uzbekistan
B. Allanazarova
Scientific research institute of hematology and blood transfusion of the Ministry of Health of the Republic of Uzbekistan
##article.numberofdownloads## 55
##article.numberofviews## 104
PDF (Русский)

Keywords

PH-ХРОМОСОМА
CHRONIC MYELOGENOUS LEUKEMIA
PH-CHROMOSOME
VARIANT TRANSLOCATION

How to Cite

Boboev, K., Assesorova, Y., Karimov, K., & Allanazarova, B. (2018). THE CASE VARIANT TRANSLOCATION T(3;9;22)(P24;Q34;Q11) IN CHRONIC MYELOID LEUKEMIA. Voprosy Onkologii, 64(6), 810–814. https://doi.org/10.37469/0507-3758-2018-64-6-810-814
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

This paper presents a case of chronic myeloid leukemia with an earlier unknown variant translocation t (3; 9; 22) (p24; q34; q11) detected by cytogenetic research using the GTG-banding technique. Despite the absence of the classical Philadelphia chromosome, the presence of chromosome 9 and 22 derivatives, as well as the BCR-ABL fusion gene, allow this translocation to be considered pathogenetic for CML. A good response of the patient to the treatment with glivec is that there is no adverse effect on the pathogenesis of the disease of an additional genetic locus (3p24) involved in complex restructuring.
https://doi.org/10.37469/0507-3758-2018-64-6-810-814
##article.numberofdownloads## 55
##article.numberofviews## 104
PDF (Русский)

References

Зельцер А.Н., Бурнашева Е.В., Шатохин Ю.В. Молекулярно-генетическая характеристика хронического миелоидного лейкоза // Журнал фундаментальной медицины и биологии. - 2016. - № 1. - С. 4-14.

Al-Achkar W., Wafa A., Ikhtiar A., Liehr T. Threeway Philadelphia translocation t(9;10;22) (q34;p11.2;q11.2) as a secondary abnormality in an imatinib mesylate-resistant chronic myeloid leukemia patient // Oncol. Lett. - 2013. - № 5. - P 1656-1658.

Asif M., Hussain A., Rasool M. A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9; 11; 22 (q34; p15; q11) in chronic myeloid leukemia: A case report // Oncology letters. - 2016. - Vol. 12. - № 3. - P. 1986-1988.

Luatti S., Baldazzi C., Marzocchi G., et. al. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy // Oncotarget. - 2017. -Vol. 8. - № 18. - P. 29906-29913.

Malvestiti F., Agrati C., Chinetti S. et. al. Complex variant of Philadelphia translocation involving chromosomes 9, 12, and 22 in a case with chronic myeloid leukaemia // Case reports in genetics. - 2014. - Vol. 2014. - P. 2-3.

Mendiola C., Ortega V., Tonk V. et. al. Complex/variant translocations in chronic myelogenous leukemia (CML): genesis and prognosis with 4 new cases // Experimental and molecular pathology. - 2014. - Vol. 97. - № 1. - P. 105-110.

Mendizabal A.M., Younes N., Levine P.H. Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia // International journal of hematology. -2016. - Т. 103. - № 1. - P 70-78.

Qin YZ., Huang X.J. Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia // Chronic Myeloid Leukemia. - Humana Press, New York, NY, 2016. - P. 1-15.

Shaffer L., McGowan-Jordan J., Schmid M. ISCN 2013. An International System for Human Cytogenetic Nomenclature (2013). Basel: Karger; 2013.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2018